FGF‐21 and 8‐OHdG Biomarkers in Drug‐Naïve Children With Autism Spectrum Disorder
International Journal of Developmental Neuroscience · 2025-11 · 85 (7)
DOI: 10.1002/jdn.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Developmental Neuroscience, online erschienen am 19.11.2025. Verfasst von Samuel Baraúna und 2 weiteren Autor:innen. Beteiligte Einrichtung: Child and Adolescent Psychiatry Lab. Psychiatry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Fibroblast Growth Factors, Deoxyguanosine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Autism spectrum disorder (ASD) is a neuropsychiatric condition characterized by significant difficulties in social communication and repetitive behaviours, with multifactorial causes that include genetic predisposition and environmental factors. Recent studies have highlighted altered levels of specific biomarkers associated with DNA damage in children with ASD. These alterations become more evident due to increased oxidative stress, a common feature in individuals diagnosed with ASD. This study aimed to investigate plasma levels of FGF‐21—an endogenous protein with metabolic and, primarily, neuroprotective functions—and its relationship with the biomarker 8OHdG, which is widely recognized as an indicator of oxidative stress and cellular and DNA damage. The research included 29 drug‐naive children diagnosed with ASD and 31 healthy control children. The 8OHdG result showed a statistically significant difference when comparing patients diagnosed with ASD to healthy controls ( t = 2.768, df = 58, p = 0.004), indicating a relevant difference in the levels of this biomarker and DNA damage between patients with ASD and controls. In contrast, the analysis of FGF‐21 ( p = 0.44) did not show a significant difference in both groups. These findings pave the way for future research that may lead to innovative therapeutic approaches for the treatment of children with ASD, focusing on reducing oxidative stress and DNA repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Child and Adolescent Psychiatry Lab. Psychiatry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Samuel Baraúna, Laiana Quagliato
Zitieren
APA
Baraúna, S., Sylvestre, G., & Quagliato, L. (2025). FGF‐21 and 8‐OHdG Biomarkers in Drug‐Naïve Children With Autism Spectrum Disorder. International Journal of Developmental Neuroscience, 85(7). https://doi.org/10.1002/jdn.70069
Vancouver
Baraúna S, Sylvestre G, Quagliato L. FGF‐21 and 8‐OHdG Biomarkers in Drug‐Naïve Children With Autism Spectrum Disorder. International Journal of Developmental Neuroscience. 2025;85(7). doi:10.1002/jdn.70069
BibTeX
@article{Barana2025,
author = {Baraúna, Samuel and Sylvestre, Gérssica and Quagliato, Laiana},
title = {FGF‐21 and 8‐OHdG Biomarkers in Drug‐Naïve Children With Autism Spectrum Disorder},
journal = {International Journal of Developmental Neuroscience},
year = {2025},
volume = {85},
number = {7},
doi = {10.1002/jdn.70069}
}
EUVIMED